Recombinant IL-6R (Tocilizumab Biosimilar) 抗体
适用: 人
ELISA, InhA
宿主: 兔
Chimeric
RhPM-1
unconjugated
Recombinant Antibody
1 image
-
- 抗原 See all IL-6R (Tocilizumab Biosimilar) products
- IL-6R (Tocilizumab Biosimilar)
- 抗体类型
- Recombinant Antibody
- 适用
- 人
-
宿主
- 兔
-
克隆类型
- Chimeric
-
标记
- This IL-6R (Tocilizumab Biosimilar) antibody is un-conjugated
-
应用范围
- ELISA, Inhibition Assay (InhA)
- 原理
- Anti-IL-6 receptor [rhPM-1 (Tocilizumab)], Rabbit IgG, kappa
- 特异性
- Tocilizumab binds specifically to both the membrane bound and soluble forms of human IL-6R. The IL6 receptor is a protein complex consisting of an IL-6 receptor subunit (IL6R) and interleukin 6 signal transducer Glycoprotein 130. Interleukin 6 (IL6) is a potent pleiotropic cytokine that regulates cell growth and differentiation and plays an important role in immune response.
- 产品特性
-
Original Species of Ab: Human
Original Format of Ab: IgG1
- 纯化方法
- Protein A affinity purified
- 纯度
- > 98 % as determined by SDS-PAGE
- 内毒素水平
- Endotoxin is < 1.0 EU/mg as determined by the LAL method
- 免疫原
- The original antibody was generated by CDR grafting of mouse PM-1 antibody onto human REI and NEW framework regions to create rhPM-1.
- 克隆位点
- RhPM-1
- 亚型
- IgG kappa
-
anti-IL-6R (Tocilizumab Biosimilar) antibody
Research Grade 适用: 人 ELISA, FACS 宿主: Humanized Monoclonal unconjugated Recombinant Antibody
-
- 应用备注
- This antibody is derived from the parental mouse clone PM-1 (PM1). Tocilizumab (TCZ) binds and neutralizes IL-6R, resulting in the inhibition of various IL-6-mediated biological activities, including inflammation-related, immunomodulatory and tissue/matrix remodelling effects. This antibody is extensively explored for its therapeutic potential in treatment of rheumatoid arthritis (PMID: 25099958, 9836380). Tocilizumab can be used in ELISA assays and is able to inhibit the growth of IL-6-dependent tumor cell lines. It inhibits sIL-6R and mIL-6R-mediated signaling. A study reported that a combination of tocilizumab and methotrexate (MTX) results in greater inhibition of joint damage and improvement in physical function than does MTX alone (PMID: 21360490). Treatment with tocilizumab results in significant improvement, maintained over time, of polyarticular-course juvenile idiopathic arthritis (pcJIA) signs and symptoms and has a safety profile consistent with that for adults with rheumatoid arthritis (PMID: 24834925). The original antibody was used for an in vivo study on ALS. Here they showed that this antibody does not affect all patients the same way. Here it was shown that the antibody lowers inflammation in patients with high inflammation and increases inflammation in patients with low inflammation (Fiala et al., 2013, PMID:23844337). tocilizumab inhibited both the transcription and secretion of cytokines and chemokines induced by apo-G37R. This showed powerful effects on the inflammation in ALS PMBC (Mizwicki et al., 2012, PMID: 23383400)
- 说明
-
This chimeric rabbit antibody was made using the variable domain sequences of the original Human IgG1 format, for improved compatibility with existing reagents, assays and techniques.
- 限制
- 仅限研究用
-
- 浓度
- 1 mg/mL
- 缓冲液
- PBS with 0.02 % Proclin 300.
- 储存液
- ProClin
- 注意事项
- This product contains ProClin: a POISONOUS AND HAZARDOUS SUBSTANCE which should be handled by trained staff only.
- 储存条件
- 4 °C,-20 °C
- 储存方法
- Store at 4°C for up to 3 months. For longer storage, aliquot and store at -20°C.
-
- 抗原
- IL-6R (Tocilizumab Biosimilar)
- Abstract
- IL-6R (Tocilizumab Biosimilar) 产品
- 物质类
- Biosimilar
- 背景
- IL6R, IL-6R, CD126, MRA, atlizumab, TCZ, Interleukin-6 receptor subunit alpha, IL-6 receptor subunit alpha, IL-6R subunit alpha, IL-6R-alpha, IL-6RA, IL-6R 1, Membrane glycoprotein 80, gp80, PM1, PM-1
- UniProt
- P08887
-
You are here:
